LRRK2 Inhibitors as Promising Treatment for Parkinson's Disease
- PMID: 39487783
- DOI: 10.1021/acschemneuro.4c00657
LRRK2 Inhibitors as Promising Treatment for Parkinson's Disease
Abstract
Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders, with current treatments offering only temporary symptomatic relief. There is an urgent need for the development of novel therapeutic approaches. Abnormal increases in LRRK2 kinase activity have been identified in both sporadic and familial PD patients, suggesting that inhibiting LRRK2 kinase activity presents a promising avenue for the pursuit of effective PD treatment strategies. In this Viewpoint, we discuss the exciting new insights regarding the development of LRRK2 kinase inhibitors as a treatment for Parkinson's disease.
Keywords: Leucine-rich repeat kinase 2; Parkinson’s disease; kinase inhibitor.
Similar articles
-
Therapeutic Targeting of Autosomal Parkinson's Disease by Modulation of Leucine-Rich Repeat Kinase 2 (LRRK2) Protein.Brain Res. 2025 Aug 1;1860:149674. doi: 10.1016/j.brainres.2025.149674. Epub 2025 May 8. Brain Res. 2025. PMID: 40345365 Review.
-
Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date.Expert Opin Ther Pat. 2024 Sep;34(9):773-788. doi: 10.1080/13543776.2024.2378076. Epub 2024 Jul 19. Expert Opin Ther Pat. 2024. PMID: 39023243 Review.
-
The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.J Med Chem. 2023 Feb 23;66(4):2282-2307. doi: 10.1021/acs.jmedchem.2c01552. Epub 2023 Feb 9. J Med Chem. 2023. PMID: 36758171 Review.
-
LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.Curr Protein Pept Sci. 2017;18(7):677-686. doi: 10.2174/1389203717666160311121748. Curr Protein Pept Sci. 2017. PMID: 26965688 Review.
-
Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.eNeuro. 2019 Dec 19;6(6):ENEURO.0453-18.2019. doi: 10.1523/ENEURO.0453-18.2019. Print 2019 Nov/Dec. eNeuro. 2019. PMID: 31685675 Free PMC article.
Cited by
-
Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson´s disease.NPJ Parkinsons Dis. 2025 Feb 17;11(1):30. doi: 10.1038/s41531-025-00881-9. NPJ Parkinsons Dis. 2025. PMID: 39962078 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical